Dexamethasoni phosphas

Administration of topical steroids is not recommended in cases of ocular redness of unknown aetiology. Patients should be monitored at frequent intervals during treatment with dexamethasone eye drops. Long-term use of corticosteroids may result in ocular hypertension/glaucoma (particularly in patients with prior steroid-induced IOP elevation or with pre-existing elevated IOP or glaucoma) and may also lead to cataract formation, especially in children and elderly patients. The use of corticosteroids may also lead to opportunistic ocular infections due to suppression of host response or delayed healing. In addition, topical ocular corticosteroids may promote, exacerbate or mask the signs and symptoms of opportunistic ocular infections. Patients with an ocular infection should receive topical steroid therapy only once the infection has been controlled with effective anti-infective treatment. These patients should be carefully and regularly monitored by an ophthalmologist. In certain specific inflammatory conditions, such as episcleritis, NSAIDs are the first-line treatment; dexamethasone should be used only when NSAIDs are contraindicated. Patients with corneal ulcers should generally not receive topical dexamethasone, except in cases where inflammation is the principal cause of delayed healing and appropriate causal therapy has already been prescribed. These patients should be carefully and regularly monitored by an ophthalmologist. Thinning of the cornea and sclera may increase the risk of perforation with the use of topical corticosteroids. Posterior subcapsular cataract may occur with cumulative doses of dexamethasone. Patients with diabetes mellitus are also more prone to developing subcapsular cataract following topical steroid administration. The use of topical steroids in allergic conjunctivitis is recommended only in severe forms of allergic conjunctivitis unresponsive to standard treatment and only for short periods. Cushing's syndrome and/or adrenal suppression associated with systemic absorption of ocular dexamethasone may occur after intensive or prolonged continuous treatment in predisposed patients, including children and patients treated with CYP3A4 inhibitors (including ritonavir and cobicistat). In such cases, treatment should be discontinued gradually. Patients with a history of contact hypersensitivity to silver should not use this product, as the drops administered may contain traces of silver. Visual disturbances Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient develops symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist should be considered for evaluation of possible causes, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR), which has been reported after systemic and topical corticosteroid use. The wearing of contact lenses should be avoided during treatment with corticosteroid eye drops.